Agios Pharm (AGIO) — Cash Flow-to-Debt Ratio
Agios Pharm (AGIO) has a Cash Flow-to-Debt Ratio of -0.70x as of June 2026, meaning its operating cash flow of $-57.31 Million could theoretically repay -1% of its total liabilities ($82.40 Million) in one year. See AGIO financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Agios Pharm Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Agios Pharm across 15 annual periods. For the full cash flow conversion analysis, see Agios Pharm (AGIO) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Agios Pharm (2011–2025)
Year-by-year debt coverage analysis for Agios Pharm. Check Agios Pharm (AGIO) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.58x | $-372.98 Million | $104.11 Million | ▼ -12.3% |
| 2024 | -3.19x | $-389.84 Million | $122.24 Million | ▼ -35.8% |
| 2023 | -2.35x | $-296.06 Million | $126.10 Million | ▼ -4.6% |
| 2022 | -2.24x | $-309.48 Million | $137.90 Million | ▲ +19.7% |
| 2021 | -2.79x | $-407.32 Million | $145.76 Million | ▼ -335.8% |
| 2020 | -0.64x | $-290.76 Million | $453.45 Million | ▲ +56.7% |
| 2019 | -1.48x | $-370.62 Million | $250.21 Million | ▲ +16.8% |
| 2018 | -1.78x | $-304.42 Million | $170.92 Million | ▼ -49.2% |
| 2017 | -1.19x | $-285.23 Million | $238.89 Million | ▼ -906.6% |
| 2016 | 0.15x | $38.56 Million | $260.50 Million | ▲ +114.4% |
| 2015 | -1.03x | $-76.95 Million | $74.95 Million | ▼ -16.8% |
| 2014 | -0.88x | $-59.35 Million | $67.54 Million | ▼ -8.6% |
| 2013 | -0.81x | $-56.40 Million | $69.72 Million | ▼ -52.0% |
| 2012 | -0.53x | $-49.55 Million | $93.11 Million | ▼ -359.2% |
| 2011 | -0.12x | $-15.22 Million | $131.33 Million | — |